Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Pfizer Geodon QT Drug Contraindication Expanded, Clarified In New Labeling

  • News

Executive Summary

Pfizer's Geodon should not be used by patients taking drugs that have a contraindication or boxed or bolded warning about QT prolongation, a labeling revision for the antypsychotic states

You may also be interested in...



Pfizer/Organon Antipsychotic Deal: Positive Thoughts On Negative Symptoms

Pfizer is paying $100 mil. up front for a second chance at the antipsychotic market through a licensing deal with Akzo Nobel's pharmaceutical division Organon

Pfizer/Organon Antipsychotic Deal: Positive Thoughts On Negative Symptoms

Pfizer is paying $100 mil. up front for a second chance at the antipsychotic market through a licensing deal with Akzo Nobel's pharmaceutical division Organon

Lundbeck Serlect NDA Revival Is One Project For CEO-Elect Braestrup

Lundbeck CEO-elect Claus Braestrup will oversee the company's renewed attempt to launch the antipsychotic Serlect (sertindole) in the U.S. when he assumes leadership of the Danish company in November

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
Latest Headlines

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

National Drug Stockpiles Create ‘False Sense Of Security’

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

See All
UsernamePublicRestriction

Register

PS039630

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By